ArticleTranslational psychiatry2026
Bridging molecules and connectome: network biomarkers guided by neurotransmitter architecture in major depressive disorder.
Article in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Major depressive disorder (MDD) involves multiscale alterations ranging from molecular signaling to large-scale brain network dysfunction. However, how molecular topography constrains system-level connectome reorganization remains inadequately understood, limiting the development of biologically grounded diagnostic markers. We established a biologically grounded framework by integrating molecular organization with systems-level connectome analysis to characterize and classify MDD. Using resting-state functional magnetic resonance imaging data from a discovery cohort of 237 first-episode, medication-naïve MDD patients and 305 healthy controls (HC), as well as an independent multi-site validation cohort comprising 243 MDD patients and 340 HCs, we systematically mapped connectome-wide reconfigurations onto 14 normative neurotransmitter receptor and transporter density distributions. Our findings revealed widespread connectivity alterations (6.38% of edges). These alterations spatially correlated with normative densities of serotonin 1A (5-HT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.